Near-Infrared Light Photobiomodulation Treatment for Retinal Vein Occlusion Macular Oedema

Inclusion Criteria: * Diagnosis macular edema secondary to branch or central vein occlusion (BRVO or CRVO) * CMT of \>300 µm and less than 550 µm; * Best corrected visual acuity of 6/6 to 6/24 (letters 87 - 53); * Intraocular pressure \< 25 mmHg; * Written informed consent has been obtained. Exclusion Criteria: * Loss of vision due to other causes (e.g. age-related macular degeneration, myopic macular degeneration, DME); * Known allergy to agents used in the study e.g. fluorescein; * Women who are pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and not using reliable means of contraception; * Only eye (vision in other eye \<6/60); * Study eye is an amblyopic eye; * Macular oedema due to other causes; * Significant diabetic retinopathy; * An ocular condition that would prevent visual acuity improvement despite resolution of oedema (such as foveal atrophy or substantial premacular fibrosis; * Previous treatment with any anti-VEGF therapy or investigational drugs in the study eye at any time prior to baseline. * Previous use of intraocular or periocular steroids in study eye at any time prior to baseline; * Cataract surgery within the last 3 months; * Retinal laser treatment within the last 6 months; * Media opacity including cataract that already precludes adequate macular photography or cataract that is likely to require surgery within 6 months; * Intercurrent severe disease such as septicaemia, any condition which would affect follow-up; * History of chronic renal failure requiring dialysis or renal transplant; * Blood pressure \>180/120; * Participant has a condition or is in a situation that in the investigator's opinion may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study